Brookline Capital Markets Analyst Recommendations & Stock PicksView the latest stock recommendations issued by analysts at Brookline Capital Markets. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Brookline Capital Markets' equity research team. MarketBeat is not affiliated with or endorsed by Brookline Capital Markets.2 AnalystsUpdated 10/7/2026 Brokerage RankingSubscribe to MarketBeat All Access to unlock brokerage rankings MarketBeatAverage Return00.00% 12-Month ROITotal Ratings14 Last 12 MonthsBuy Ratings10 Last 12 MonthsSell Ratings0 Last 12 MonthsCompanies Covered14 Last 12 Months 10 25 50 100 250 500 Show Full History Latest Per Company Records Reporting Date RatingAll RatingsStrong BuyBuyHoldSell ActionAll ActionsUpgradesDowngradesInitiates CoverageRaises TargetLowers TargetReiterates RatingPrice Target Change Any Change Raised 5%+ Raised 10%+ Raised 20%+ Lowered 5%+ Lowered 10%+ Lowered 20%+ Price Target Change Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors Communication ServicesConsumer DiscretionaryConsumer StaplesEnergyFinanceHealthcareIndustrialsMaterialsReal EstateTechnologyUtilities Market Cap All Market Caps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter More filters Fewer filters Clear all Done Clear all 0 Results Export CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsBMEABiomea Fusion$1.26-7.4%10/7/2026Kumaraguru RajaSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy00.00%View details for Brookline Capital Markets rating of Biomea Fusion (NASDAQ:BMEA) on 10/7/2026CRBUCaribou Biosciences$0.47-5.4%10/7/2026Leah CannSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeBuy ➝ Hold00.00%View details for Brookline Capital Markets rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026RVMDRevolution Medicines$188.44-2.8%9/28/2026Leah RushSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated Coverage$318.00Buy00.00%View details for Brookline Capital Markets rating of Revolution Medicines (NASDAQ:RVMD) on 9/28/2026MRNAModerna$216.25+1.2%8/19/2026 Reiterated RatingBuy00.00%View details for Brookline Capital Markets rating of Moderna (NASDAQ:MRNA) on 8/19/2026SCYXSCYNEXIS$3.99-1.0%7/31/2026 Reiterated RatingBuy00.00%View details for Brookline Capital Markets rating of SCYNEXIS (NASDAQ:SCYX) on 7/31/2026LNTHLantheus$100.02-0.1%7/28/2026 DowngradeStrong-Buy ➝ Hold00.00%View details for Brookline Capital Markets rating of Lantheus (NASDAQ:LNTH) on 7/28/2026CLRBCellectar Biosciences$1.39-2.8%7/12/2026 UpgradeStrong-Buy00.00%View details for Brookline Capital Markets rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/12/2026EDSAEdesa Biotech$2.85-3.1%6/29/2026 UpgradeStrong-Buy00.00%View details for Brookline Capital Markets rating of Edesa Biotech (NASDAQ:EDSA) on 6/29/2026KYMRKymera Therapeutics$106.68-4.8%6/8/2026 Reiterated RatingBuy00.00%View details for Brookline Capital Markets rating of Kymera Therapeutics (NASDAQ:KYMR) on 6/8/2026PMNPromis Neurosciences$8.66-8.4%5/20/2026 UpgradeStrong-Buy00.00%View details for Brookline Capital Markets rating of Promis Neurosciences (NASDAQ:PMN) on 5/20/2026 MarketBeat Community Rating for Brookline Capital MarketsMarketBeat's community ratings are surveys of what our community members think about Brookline Capital Markets and other research firms in the last 90 days. Vote "Outperform" if you believe Brookline Capital Markets's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Brookline Capital Markets's recommendations will underperform the broader market over the long term. You may vote once every thirty days. Log in to vote on this brokerage. COMMUNITY RATINGS0.0out of 5 (last 90 days)0 of 5 stars OUTPERFORM VOTES 0 Believe will outperform the market UNDERPERFORM VOTES 0 Believe will underperform the market Analysts at Brookline Capital MarketsBrookline Capital Markets' equity research team has issued ratings on 14 companies across 1 sectors over the past 12 months, covered by 2 analysts. The Brookline Capital Markets analysts below are listed by number of ratings issued in the last year.Leah CannSubscribe to MarketBeat All Access to unlock analyst rankings1 RatingLeah RushSubscribe to MarketBeat All Access to unlock analyst rankings1 RatingBrookline Capital Markets Stock Coverage by SectorBrookline Capital Markets concentrates its research most heavily in Healthcare (100.0%). The chart below shows how Brookline Capital Markets' 14 rated companies are distributed across all 1 sector it covers.Healthcare14 companies100.0% Brookline Capital Markets - Frequently Asked Questions What stocks does Brookline Capital Markets currently recommend buying? Brookline Capital Markets' analysts currently have buy-equivalent ratings on 10 companies. What sectors does Brookline Capital Markets specialize in? Brookline Capital Markets has the deepest coverage in Healthcare (100.0% of rated companies). How often does Brookline Capital Markets change its stock ratings? Brookline Capital Markets issued 14 ratings over the last 12 months across 14 companies — an average of roughly 1 rating actions per month. These include downgrade, initiated coverage, reiterated rating and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Brookline Capital Markets analyst actions. Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageJefferies Financial GroupWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
